Back to top
more

biote Corp. (BTMD)

(Delayed Data from NSDQ)

$5.23 USD

5.23
71,103

+0.13 (2.55%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $5.24 +0.01 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts See an 88.04% Upside in biote Corp. (BTMD): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at an 88% upside potential for biote Corp. (BTMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is biote Corp. (BTMD) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks.com featured highlights include Steelcase Carriage Services, biote and Acme United

by Zacks Equity Research

Steelcase Carriage Services, biote and Acme United have been highlighted in this Screen of The Week article.

Moumita C. Chattopadhyay headshot

Buy These 4 Stocks With Rising Cash Flows for Big Gains

by Moumita C. Chattopadhyay

Cash indicates a company's true financial health. It is the key to its existence, development and success. SCS, CSV, BTMD and ACU are worth buying given their rising cash flows.

Zacks.com featured highlights include Ardmore Shipping, TXO Partners, GeoPark and biote

by Zacks Equity Research

Ardmore Shipping, TXO Partners, GeoPark and biote are part of the Zacks Screen of the Week article.

biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

biote Corp. (BTMD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Moumita C. Chattopadhyay headshot

Buy 4 Stocks With Rising Cash Flows to Enrich Your Portfolio

by Moumita C. Chattopadhyay

Achieving profit is, no doubt, a company's goal, but having a healthy cash flow is imperative to its existence, development and success. So, ASC, TXO, GPRK and BTMD are worth buying.

Are Medical Stocks Lagging Intuitive Surgical (ISRG) This Year?

by Zacks Equity Research

Here is how Intuitive Surgical, Inc. (ISRG) and biote Corp. (BTMD) have performed compared to their sector so far this year.

Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics

by Zacks Equity Research

ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Wall Street Rally

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.

Haemonetics (HAE) Banks on Growing Hospital Arm, New Launches

by Zacks Equity Research

Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.

Wall Street Analysts Think biote Corp. (BTMD) Could Surge 25.44%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 25.4% in biote Corp. (BTMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

biote Corp. (BTMD) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

biote Corp. (BTMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

biote Corp. (BTMD) Surges 10.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

biote Corp. (BTMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Biote Corp. (BTMD) Q1 Earnings Beat Estimates

by Zacks Equity Research

biote Corp. (BTMD) delivered earnings and revenue surprises of 360% and 0.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 11.59% and 2.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate QuidelOrtho (QDEL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aurora Cannabis (ACB) Moves 46.0% Higher: Will This Strength Last?

by Zacks Equity Research

Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Earnings Preview: biote Corp. (BTMD) Q1 Earnings Expected to Decline

by Zacks Equity Research

Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate biote Corp. (BTMD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Biote Corp. (BTMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ICU Medical (ICUI) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

ICU Medical (ICUI) delivered earnings and revenue surprises of 33.05% and 4.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Biote Corp. (BTMD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

biote Corp. (BTMD) delivered earnings and revenue surprises of -237.50% and 4.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Biote Corp. (BTMD) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

biote Corp. (BTMD) delivered earnings and revenue surprises of 340% and 5.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of 58.33% and 3.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Q2 Earnings Meet Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 0% and 2.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?